Concurrent Chemoradiotherapy with Weekly Paclitaxel for Locally Advanced Non-small Cell Lung Cancer

Seong-Hyun JEONG; Jae-Ho JUNG; Hyun-Woo LEE; Seok-Yun KANG; Yong-Won CHOI; Mi-Sun AHN; Yun-Ho HWANG; Young-Taek OH; Jin-Hyuk CHOI; Seung-Soo SHEEN; Kwang-Joo PARK.
Journal of Lung Cancer ; : 8-12, 2009.
Artículo en Ko | WPRIM | ID: wpr-54358

Documentos relacionados

  1. Nanoparticle-Based Radiosensitization.
  2. O02.03 Value of adding erlotinib to thoracic radiation therapy with chemotherapy for stage III non-small cell lung cancer: a prospective phase II study.
  3. Comparison of efficacy and safety between simultaneous integrated boost intensity-modulated radiotherapy and standard-dose intensity-modulated radiotherapy in locally advanced esophageal squamous cell carcinoma: a retrospective study.
  4. Ferroptosis: Frenemy of Radiotherapy.
  5. Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for Stage II or III breast cancer.
  6. CT density in lung cancer patients after radiotherapy sensitized by metoclopramide. A subgroup analysis of a randomized trial.
  7. Nitro rotation tuned dissociative electron attachment upon targeted radiosensitizer 4-substituted <i>Z</i> bases.
  8. Preliminary results of randomized phase II study of etoposide plus lobaplatin or etoposide plus cisplatin with concurrent thoracic radiotherapy in the treatment of limited-stage small cell lung cancer.
  9. Electron attachment to fluorodeoxyglucose: Dissociation dynamics in a molecule of near-zero electron affinity.
  10. Predictive role of circulatory levels of high-mobility group box 1 for radiation pneumonitis in patients with non-small cell lung cancer treated with definitive thoracic radiotherapy.